Health technology assessment (HTA) is a systematic process governments and health systems use to decide whether a new drug, device, diagnostic test, or medical procedure is worth paying for. It weighs clinical effectiveness, cost, safety, and broader social impact to answer a deceptively simple question: does this technology deliver enough benefit to justify its price? Nearly every country with a public health system relies on some form of HTA to guide spending decisions, and its conclusions often determine whether patients can access a new treatment.
What HTA Actually Evaluates
HTA goes far beyond asking “does this treatment work?” It examines a technology’s direct and indirect consequences across multiple dimensions. The most widely used framework, developed by European HTA agencies, organizes the assessment into nine domains: the health problem and current treatment options, the technical characteristics of the new technology, safety, clinical effectiveness, costs and economic value, ethical considerations, organizational impact on hospitals and health systems, social effects, and legal implications.
In practice, the two domains that carry the most weight are clinical effectiveness and cost. Reviewers gather all available trial data on how well a treatment works compared to existing options, then pair that with an economic analysis asking whether the health gains are proportional to the price. But the other domains matter too. A new surgical robot might be clinically effective and cost-acceptable, yet require hospitals to retrain entire surgical teams (an organizational concern) or raise questions about equitable access for rural patients (a social concern). HTA tries to capture the full picture.
How Cost-Effectiveness Is Measured
The core metric in most HTA systems is the quality-adjusted life year, or QALY. A QALY combines how long a treatment helps someone live with how well they live during that time. One QALY equals one year of life in perfect health. A treatment that extends life by two years but at significantly reduced quality might generate fewer QALYs than one that adds a single year of good health.
Analysts then calculate the incremental cost-effectiveness ratio: how much extra money the new treatment costs for each additional QALY it produces compared to the current standard of care. That number gets compared against a threshold. In England, the National Institute for Health and Care Excellence (NICE) typically considers treatments cost-effective if they fall between £20,000 and £30,000 per QALY gained. For end-of-life treatments, NICE allows up to £50,000 per QALY, and for rare diseases, the threshold can stretch to £100,000 to £300,000. In the United States, the Institute for Clinical and Economic Review (ICER) uses a benchmark range of $100,000 to $150,000 per QALY.
These thresholds are not hard cutoffs. Committees weigh uncertainty in the evidence, the severity of the condition, whether alternatives exist, and how many patients are affected. A treatment that comes in slightly above the threshold but addresses a condition with no other options may still receive a positive recommendation.
The Assessment Process
An HTA typically begins when a new technology is approaching or has recently received regulatory approval. The HTA agency identifies it as a priority, often through horizon scanning, which tracks drugs and devices in late-stage development. A manufacturer then submits clinical trial data, an economic model, and sometimes patient-reported evidence supporting the technology’s value.
An independent review team analyzes the submission. They scrutinize the clinical evidence for quality and relevance, rebuild or stress-test the economic model, and flag uncertainties. In the NICE system, an external review group produces its own “most plausible” cost-effectiveness estimate, which often differs from the manufacturer’s. A committee of clinicians, economists, patient representatives, and other experts then discusses the findings in detail and selects the base-case analysis that will drive the recommendation.
The final output is a recommendation: fund the technology, reject it, or fund it only under certain conditions (for specific patient groups, at a negotiated price, or with a requirement to collect more data). In many countries, this recommendation directly determines whether the treatment enters the public formulary and at what price.
How HTA Shapes Drug Pricing
HTA recommendations don’t just approve or reject treatments. They create powerful leverage in price negotiations between manufacturers and health systems. When an assessment finds that a drug’s price exceeds the cost-effectiveness threshold, the manufacturer often has a choice: lower the price or lose access to an entire national market.
This dynamic has grown more complex over time. Many agreements now involve confidential rebates, where the list price stays high but the health system pays less through undisclosed discounts. Other arrangements include price-volume agreements (the price per unit drops as more patients use the drug) and outcomes-based contracts (payment depends on how well the drug performs in real patients). France’s comparatively high uptake of new cancer drugs, for example, is partly explained by its use of price-volume agreements and a funding mechanism that reimburses hospitals for new drugs outside standard hospital budgets.
The growing use of these confidential arrangements makes it harder to study HTA’s true impact on drug pricing. But the link is clear: in countries with formal HTA processes, manufacturers routinely adjust their pricing strategies to meet cost-effectiveness thresholds.
Major HTA Agencies Worldwide
Most high-income countries have at least one HTA body. NICE, established in England in 1999, is among the most influential and often sets methodological standards that other agencies follow. Canada’s CADTH evaluates drugs and health technologies for federal and provincial coverage decisions. Germany’s IQWiG provides independent assessments of the benefits of medical interventions for the country’s statutory health insurance system. Australia’s PBAC has required cost-effectiveness evidence for drug reimbursement since 1993, making it one of the earliest adopters of formal HTA.
Other notable agencies include Belgium’s KCE, Ireland’s HIQA, Sweden’s SBU, New Zealand’s PHARMAC, and Quebec’s INESSS. In the United States, which lacks a single-payer system, ICER operates as an independent nonprofit rather than a government body. Its reports don’t carry the binding authority that NICE recommendations do, but they increasingly influence coverage and pricing discussions among insurers.
The EU’s Joint Assessment Framework
A major shift in European HTA took effect in January 2025. EU Regulation 2021/2282, which entered into force in January 2022, created a system of joint clinical assessments across EU member states. Starting with cancer medicines and advanced therapy medicinal products, a single clinical assessment now serves all member countries, reducing duplication. Each country still makes its own pricing and reimbursement decisions, but the underlying evaluation of clinical evidence is shared.
This regulation also requires manufacturers to submit information early in development, allowing HTA bodies to provide joint scientific advice alongside the European Medicines Agency. The goal is to align the evidence companies collect during clinical trials with the evidence HTA bodies will eventually need for their assessments.
The Role of Real-World Evidence
HTA has traditionally relied on randomized controlled trials as the gold standard of clinical evidence. But there is growing recognition that trial data alone doesn’t always reflect how a treatment performs in everyday clinical practice. Trials enroll carefully selected patients, follow strict protocols, and run for limited periods. Real-world evidence, drawn from electronic health records, insurance claims, patient registries, and other routine data sources, can fill those gaps.
Several HTA agencies, including NICE, CADTH, and France’s HAS, have published guidelines on when and how real-world evidence can inform their decisions. The consensus is not that real-world data should replace trials, but that the two types of evidence are complementary. Real-world evidence is especially valuable for understanding long-term outcomes, identifying rare side effects, and assessing whether a drug works as well in diverse patient populations as it did in trial settings.
Patient Involvement in the Process
HTA agencies increasingly seek input from patients and patient organizations. Clinical trials measure outcomes like tumor shrinkage or blood pressure reduction, but patients may care more about fatigue, the ability to work, or side effects that don’t show up in primary trial endpoints. Patient testimony and survey data can surface these priorities.
How agencies involve patients varies. Some invite patient representatives to sit on appraisal committees. Others accept written submissions describing lived experience with the condition and its treatments. A comparative analysis of HTA practices across seven countries (Canada, England, Scotland, France, Germany, Spain, and Italy) found that the most effective approaches share common features: clear frameworks for what patient input looks like, involvement early in the process rather than as an afterthought, and support to help patient groups build the capacity to engage meaningfully with complex technical assessments. As the EU rolls out its joint clinical assessment framework, there is a push to embed these practices from the start.